MPL and Congenital thrombocytopenia: To identify the optimal concentration of decitabine for increasing thrombocyte counts independent of Mpl signaling, 24 hpf Tg(mpl:eGFP)smu4;mplsmu3 embryos, characterized by mpl-deficiency and congenital thrombocytopenia, with thrombocytes specifically marked by GFP expression, were treated with different concentrations (10–50 μM) of decitabine for 3 days (Fig. 1A).